Open AccessClinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
Author(s) -
Edouard Martin,
Mark T. Smith,
Bradley J. Maroni,
Qing Zuraw,
Emil M. deGoma
Publication year - 2017
Publication title -
american journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 85
eISSN - 1421-9670
pISSN - 0250-8095
DOI - 10.1159/000464476
Subject(s) - medicine , placebo , anemia , kidney disease , tolerability , gastroenterology , ferritin , adverse effect , clinical endpoint , hemoglobin , randomized controlled trial , pathology , alternative medicine
Therapeutic options for the treatment of anemia secondary to chronic kidney disease (CKD) remain limited. Vadadustat (AKB-6548) is an oral hypoxia-inducible factor prolyl-hydroxylase domain (HIF-PHD) inhibitor that is being investigated for the treatment of anemia secondary to CKD.